MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targetingMALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting

NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis

2026/02/20 00:01
3 min read

MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared NexEos’s Investigational New Drug (IND) Application to proceed to a Phase II/III clinical trial of NTX-1024 for the treatment of patients with the rare disease, vernal keratoconjunctivitis (VKC). The planned Phase II/III trial is a single, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of NTX-1024 ophthalmic solution in patients with VKC.

This is on the heels of the positive results reported from an open-label, investigator-initiated study evaluating the efficacy, safety, and tolerability of NTX-1024 eye drops in adults with VKC. The study was conducted in Mexico and enrolled 15 patients with mild to moderate VKC who received NTX-1024 four times daily over a four-week period. Treatment led to significant improvement in patient-reported symptoms such as itching and quality of life, along with reductions in clinical signs of inflammation, including hyperemia and corneal fluorescein staining. NTX-1024 was also found to be safe and well-tolerated.

This marks the first clinical study to evaluate NTX-1024 in VKC, a rare and severe eosinophil-driven ocular condition that can lead to irreversible ocular damage, including vision loss, if left untreated. These results reinforce the therapeutic potential of NTX-1024 in VKC and have prompted NexEos to pursue further clinical development.

In addition, on January 16, 2026, the FDA granted Orphan Drug Designation to NTX-1024 for VKC.

“Clearance of our IND application, which included data from our open-label investigator-initiated study in Mexico, is an important and meaningful step for the program,” said Steve Tullman, CEO and Chairman of NexEos. “We are excited to advance clinical development of NTX-1024, which would be the first, ophthalmic therapeutic to neutralizes eosinophil cationic protein to reduce inflammation in rare forms of Allergic Conjunctivitis – Vernal Keratoconjunctivitis (VKC) and Atopic Keratoconjunctivitis (AKC). We are on track to initiate our Phase II/III clinical trial by the second half of this year, taking us closer to our objective of delivering a best-in-class therapeutic option to patients with VKC.”

About Vernal Keratoconjunctivitis (VKC)

VKC is a rare, chronic, and vision-threatening ocular inflammatory disease that is predominantly eosinophil-mediated. Activated eosinophils release toxic granule proteins, including eosinophil major basic protein-1 (eMBP1), resulting in damage to the ocular surface (Sacchetti, et al. 2021). VKC primarily affects children although approximately 10% of cases persist into adulthood (Di Zazzo A 2024). Uncontrolled VKC can result in severe ocular damage and permanent vision loss (Vichyanond, et al. 2014).

About NTX-1024 (gleceparin sodium)

NTX-1024 is a novel, topical ophthalmic solution targeting eosinophil cationic protein mediated inflammation in rare forms of allergic conjunctivitis, including VKC and AKC. NTX-1024 has completed proof of concept in VKC, received ODD approval, and now has FDA clearance of its IND application to advance to a Phase II/III clinical trial in VKC. NTX-1024 is the first therapeutic successfully targeting neutralization of eosinophil cationic proteins. Finally, NTX-1024 has the potential to be the first drug to be disease-modifying and steroid-sparing in VKC and AKC.

About NexEos Bio

NexEos Bio (www.nexeosbio.com) is a privately held medical diagnostics and therapeutics company based in Malvern, Pennsylvania, dedicated to improving the detection, diagnosis, treatment and life-long management of patients living with chronic, eosinophil-related inflammatory diseases. Through the licensing, development and commercialization of novel technologies, NexEos Bio is bringing new tools and therapies to market that address the unmet needs of patients suffering from eosinophil-related diseases.

Contacts

For more Information, please send inquiries to: [email protected]

Market Opportunity
NuNet Logo
NuNet Price(NTX)
$0.00691
$0.00691$0.00691
+3.44%
USD
NuNet (NTX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Daily market key data review and trend analysis, produced by PANews.
Share
PANews2025/04/30 13:50
Why LYNO’s Presale Could Trigger the Next Wave of Crypto FOMO After SOL and PEPE

Why LYNO’s Presale Could Trigger the Next Wave of Crypto FOMO After SOL and PEPE

The post Why LYNO’s Presale Could Trigger the Next Wave of Crypto FOMO After SOL and PEPE appeared on BitcoinEthereumNews.com. Cryptocirca has never been bereft of hype cycles and fear of missing out (FOMO). The case of Solana (SOL) and Pepe (PEPE) is one of the brightest examples that early investments into the correct projects may yield the returns that are drifting. Today there is an emerging rival in the limelight—LYNO. LYNO is in its presale stage, and already it is being compared to former breakout tokens, as many investors are speculating that LYNO will be the next big thing to ignite the market in a similar manner. Early Bird Presale: Lowest Price LYNO is in the Early Bird presale and costs only $0.050 for each token; the initial round will rise to $0.055. To date, approximately 629,165.744 tokens have been sold, with approximately $31,458.287 of that amount going towards the $100,000 project goal.  The crypto presales allow investors the privilege to acquire tokens at reduced prices before they become available to the general market, and they tend to bring substantial returns in the case of great fundamentals. The final goal of the project: 0.100 per token. This gradual development underscores increasing investor confidence and it brings a sense of urgency to those who wish to be first movers. LYNO’s Edge in a Competitive Market LYNO isn’t just another presale token—it’s a powerful AI-driven cross-chain arbitrage platform designed to deliver real utility and long-term growth. Operating across 15+ blockchains, LYNO’s AI engine analyzes token prices, liquidity, volume, and gas fees in real-time to identify the most profitable trade routes. It integrates with bridges like LayerZero, Wormhole, and Axelar, allowing assets to move instantly across networks, so no opportunity is missed.  The platform also includes community governance, letting $LYNO holders vote on protocol upgrades and fee structures, staking rewards for long-term investors, buyback-and-burn mechanisms to support token value, and audited smart…
Share
BitcoinEthereumNews2025/09/18 16:11
Nvidia’s Strategic Masterstroke: Deepening Early-Stage Ties with India’s Booming AI Startup Ecosystem

Nvidia’s Strategic Masterstroke: Deepening Early-Stage Ties with India’s Booming AI Startup Ecosystem

BitcoinWorld Nvidia’s Strategic Masterstroke: Deepening Early-Stage Ties with India’s Booming AI Startup Ecosystem NEW DELHI, INDIA – October 2025: Nvidia Corporation
Share
bitcoinworld2026/02/20 09:30